← FDA DRUG APPROVALS

FDA ANDA · ANDA202052

PANTOPRAZOLE SODIUM

Sponsor: ORBION PHARMS

APPLICATION
ANDA202052
TYPE
ANDA
ORIGINAL APPROVAL
2014-12-02
LATEST ACTION
2024-04-16
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

PANTOPRAZOLE SODIUMPrescription
PANTOPRAZOLE SODIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL
PANTOPRAZOLE SODIUMPrescription
PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2024-04-16Labeling · Supplement 10 · standardAP
2022-08-15Labeling · Supplement 8 · standardAP
2022-08-15Labeling · Supplement 9 · standardAP
2019-07-22Labeling · Supplement 6 · standardAP
2019-07-22Labeling · Supplement 2 · standardAP
2019-07-22Labeling · Supplement 7 · standardAP
2019-07-22Labeling · Supplement 5 · standardAP
2019-07-22Labeling · Supplement 3 · standardAP
2015-04-08Labeling · Supplement 1 · standardAP
2014-12-02Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →